270 related articles for article (PubMed ID: 31027840)
1. Evaluation of new medicines in Spain and comparison with other European countries.
Epstein D; Espín J
Gac Sanit; 2020; 34(2):133-140. PubMed ID: 31027840
[TBL] [Abstract][Full Text] [Related]
2. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
[TBL] [Abstract][Full Text] [Related]
3. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries.
Angelis A; Lange A; Kanavos P
Eur J Health Econ; 2018 Jan; 19(1):123-152. PubMed ID: 28303438
[TBL] [Abstract][Full Text] [Related]
4. Deliberative processes in health technology assessment of medicines: the case of Spain.
Pinilla-Dominguez P; Pinilla-Dominguez J
Int J Technol Assess Health Care; 2023 Jul; 39(1):e50. PubMed ID: 37403252
[TBL] [Abstract][Full Text] [Related]
5. Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union.
Beletsi A; Koutrafouri V; Karampli E; Pavi E
Value Health Reg Issues; 2018 Sep; 16():81-91. PubMed ID: 30316029
[TBL] [Abstract][Full Text] [Related]
6. Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?
Oliva-Moreno J; Puig-Junoy J; Trapero-Bertran M; Epstein D; Pinyol C; Sacristán JA
Value Health; 2020 Jan; 23(1):25-31. PubMed ID: 31952669
[TBL] [Abstract][Full Text] [Related]
7. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries.
Kleijnen S; Lipska I; Leonardo Alves T; Meijboom K; Elsada A; Vervölgyi V; d'Andon A; Timoney A; Leufkens HG; De Boer A; Goettsch WG
Ann Oncol; 2016 Sep; 27(9):1768-75. PubMed ID: 27329251
[TBL] [Abstract][Full Text] [Related]
8. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
9. Determinants of Managed Entry Agreements in the context of Health Technology Assessment: a comparative analysis of oncology therapies in four countries.
Efthymiadou O; Kanavos P
Int J Technol Assess Health Care; 2021 Jan; 37():e31. PubMed ID: 33509311
[TBL] [Abstract][Full Text] [Related]
10. Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework.
Angelis A; Linch M; Montibeller G; Molina-Lopez T; Zawada A; Orzel K; Arickx F; Espin J; Kanavos P
Soc Sci Med; 2020 Feb; 246():112595. PubMed ID: 31874372
[TBL] [Abstract][Full Text] [Related]
11. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.
Bloem LT; Vreman RA; Peeters NWL; Hoekman J; van der Elst ME; Leufkens HGM; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
Clin Transl Sci; 2021 Jul; 14(4):1566-1577. PubMed ID: 33786991
[TBL] [Abstract][Full Text] [Related]
12. Similarities and differences between stakeholders' opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey.
Vokó Z; Cheung KL; Józwiak-Hagymásy J; Wolfenstetter S; Jones T; Muñoz C; Evers SM; Hiligsmann M; de Vries H; Pokhrel S;
Health Res Policy Syst; 2016 May; 14(1):38. PubMed ID: 27230485
[TBL] [Abstract][Full Text] [Related]
13. Comparing access to orphan medicinal products in Europe.
Zamora B; Maignen F; O'Neill P; Mestre-Ferrandiz J; Garau M
Orphanet J Rare Dis; 2019 May; 14(1):95. PubMed ID: 31053154
[TBL] [Abstract][Full Text] [Related]
14. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
15. Patient advocacy group involvement in health technology assessments: an observational study.
Single A; Cabrera A; Fifer S; Tsai J; Paik JY; Hope P
Res Involv Engagem; 2021 Nov; 7(1):83. PubMed ID: 34823610
[TBL] [Abstract][Full Text] [Related]
16. A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries.
Zozaya N; Villaseca J; Fernández I; Abdalla F; Cadenas-Noreña B; Calleja MÁ; Gómez-Pajuelo P; Mestre-Ferrándiz J; Oliva-Moreno J; Trillo JL; Hidalgo-Vega Á
Appl Health Econ Health Policy; 2024 May; 22(3):297-313. PubMed ID: 38214848
[TBL] [Abstract][Full Text] [Related]
17. Applying rapid 'de-facto' HTA in resource-limited settings: experience from Romania.
Lopert R; Ruiz F; Chalkidou K
Health Policy; 2013 Oct; 112(3):202-8. PubMed ID: 23953877
[TBL] [Abstract][Full Text] [Related]
18. Paradigms in operation: explaining pharmaceutical benefit assessment outcomes in England and Germany.
Kieslich K
Health Econ Policy Law; 2020 Jul; 15(3):370-385. PubMed ID: 30975237
[TBL] [Abstract][Full Text] [Related]
19. The Development of the Romanian Scorecard HTA System.
Radu CP; Chiriac ND; Pravat AM
Value Health Reg Issues; 2016 Sep; 10():41-47. PubMed ID: 27881276
[TBL] [Abstract][Full Text] [Related]
20. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
Nicod E
Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
